Paysign's strategic focus on Plasma and Patient Affordability programs has driven significant growth. Read more to see why PAYS stock is a Buy.

ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare. ...

But ironically, the company has benefited from winning tenders to counter the impact of the avian flu pandemic which has ...

By focusing on dominant ASX shares like CSL, Goodman Group, WiseTech Global, and Xero, investors can build a portfolio of high-quality stocks that have the potential to compound wealth over the ...

Due to the planned CSL transition, Plasma revenue declined 9% in the quarter ... and that's just a function of pay-for-performance and the fact that we're not where we need to be across the ...

We believe CSL's valuation multiple de-rate is onerous considering the growth outlook, particularly for IG therapies. Key risks include: (1) US inflation impacting plasma donor fees, (2 ...

#1. CSL Key milestones: 2007: CSL hit $100 before its 3-for-1 split. 2015: CSL hit $100 (again) 2018: Cracked $200. 2020: First surpassed $300. Note: CSL would technically be above $500 were it not ...

For example, the team at Goldman Sachs has just initiated coverage on the plasma therapies leader with a buy rating and $325.40 price target. It said: Our Buy recommendation for CSL is driven by ...

The Experimental Advanced Superconducting Tokamak (EAST), often referred to as China’s 'artificial sun,' successfully sustained plasma for a record 1,000 seconds, or over 17 minutes. This ...